TB-500: The Acetylated Actin-Binding Heptapeptide and Why It Is Not Thymosin Beta-4

A synthetic heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, TB-500 corresponds to the actin-binding region of thymosin beta-4 — residues 17 to 23 of a 43-residue parent protein. The point that matters most is also the one most often blurred: this is not thymosin beta-4 but a short piece of it, and marketing copy and second-hand literature summaries habitually treat the two as interchangeable. Our TB-500 for research comes as lyophilized powder in sealed vials, for laboratory use only.

Defining TB-500

Thymosin beta-4, an intracellular protein of 43 residues, ranks among the most plentiful peptides in mammalian cells. Its best-established job is binding monomeric G-actin and maintaining a reservoir the cell can feed into filament assembly whenever the cytoskeleton has to be rebuilt — which is what happens when cells migrate, and therefore when tissue repairs itself. Actin binding is handled by a short central motif built around the sequence LKKTETQ.

Synthesised on its own and acetylated at the N-terminus, that motif is TB-500. Since the parent protein does more than bind actin — reported involvement in inflammation, angiogenesis and cell survival that does not all reduce to this heptapeptide — results obtained with the intact 43-residue protein cannot be presumed to describe the fragment. The distinction is real and consequential, and our article on the fragment versus the whole protein goes further into it.

Origin and structure

• Sequence. Seven residues, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, linear and acetylated at the N-terminus, with no disulfide bridges.
• The acetyl cap. Removing the free amine and its positive charge protects the peptide from aminopeptidases and recreates the environment the motif sits in within the parent protein.
• Identifiers. Formula C38H68N10O14, CAS 885340-08-9, molecular weight 889.02 Da — among the smallest peptides we list.
• Composition. A pair of lysines leaves it positively charged at neutral pH and very soluble in water. With no cysteine, methionine or aromatic residues, there is no disulfide to manage, no oxidation risk, and essentially no absorbance at 280 nm.

The proposed mechanism

What the LKKTETQ motif is thought to do is sequester actin. Binding monomeric G-actin shifts the balance between free monomer and assembled F-actin filaments, and remodelling of that kind is what allows cells to migrate — fibroblasts, endothelial cells and keratinocytes moving into damaged tissue. Published downstream observations include more endothelial migration in angiogenesis assays and quicker closure in wound-repair models.

Two honest reservations apply. The first is that any seven-residue peptide is intrinsically a weak binder: affinity for actin is modest, and the outcome depends on concentration in a way a high-affinity ligand's would not. The second is that thymosin beta-4 functions inside the cell, and published work has not fully settled how a heptapeptide applied externally reaches the intracellular actin pool; some authors suggest additional or alternative extracellular routes. Any laboratory working with TB-500 should regard actin sequestration as the leading hypothesis rather than as established pharmacology in their particular system.

There is also a naming problem that deserves to be stated openly. Vendors routinely sell the heptapeptide labelled as thymosin beta-4, and reviews sometimes cite studies of the complete protein to back claims about the fragment. Given a more than fivefold difference in mass and almost no shared sequence, this is not a matter of labelling etiquette — it decides which literature applies to the vial in front of you. The dependable test is the certificate: a mass around 889 Da means the fragment, a mass around 4,963 Da means the protein. Product names and everything else are just claims.

What has been studied

• Cell work. Actin binding and polymerisation assays, migration assays in endothelial cells and fibroblasts, and scratch-closure experiments.
• Rodent work. Dermal wound models, cardiac injury models — a substantial strand, given that much of the thymosin beta-4 literature began in cardiac research — plus tendon and muscle injury models.
• Trials of the full-length protein. Human trials have been run with the complete 43-residue protein in dermal and ocular surface indications. They concern a different molecule and cannot be offered as evidence for the fragment.
• Human evidence for TB-500. Effectively none; no human trial programme for the heptapeptide has been published.

Where this literature came from also affects how it should be read. Interest in thymosin beta-4 grew out of research on cardiac repair and activation of epicardial cells, and several of the most-cited mechanistic results come from that context rather than from dermal, tendon or muscle models. Cardiac tissue involves cell populations and signalling settings that need not generalise, so a claim originating in cardiac work should be flagged as such instead of being offered as a general property of the peptide.

Presentations available

Consider what the small mass means in molar terms: 5 mg of this peptide is about 5.6 micromoles, while 5 mg of a 4 kDa peptide is about 1.2 micromoles. Comparing differently sized peptides by milligram is meaningless, which is why molar thinking matters — see molecular weight and moles. TB-500 also features in blends, among them the Wolverine blend and a topical cream, all inside the collection of tissue repair peptides.

Reconstitution and storage at the bench

Worked through: 2 mL of bacteriostatic water added to a 5 mg vial produces 2.5 mg/mL, that is 2,500 mcg/mL, so every 0.1 mL of that solution holds 250 micrograms of peptide — for this molecule, roughly 281 nanomoles. Few peptides are easier to prepare: it is small, dissolves readily in water, has no disulfide bridge, carries no oxidation-prone residues and shows no tendency to aggregate.

Keep sealed lyophilized powder at minus 20 degrees Celsius, dark and dry; keep reconstituted solution at 2 to 8 degrees Celsius and use it inside the study window. Split it into aliquots at reconstitution instead of freezing and thawing one tube repeatedly. One warning applies specifically to very small peptides: at low concentrations, loss by adsorption to glass and plastic is proportionally large, so low-binding plasticware and carrier protein in assay buffers are the standard remedies. Our reconstitution guide has more.

Purity, the COA and how to read it

You should receive an HPLC trace stating main-peak area percentage, a mass spectrometry identity result against the theoretical 889.02 Da, net peptide content, the lot number and the analysis date. Three checks belong to this peptide in particular. First, the acetyl group: without it the heptapeptide is 42 daltons lighter, a difference mass spectrometry resolves easily and one worth confirming, since acetylation is part of the molecule rather than a byproduct of synthesis. Second, the detection wavelength: lacking aromatic residues, the peptide must be quantified near 214 nm, so a chromatogram recorded only at 280 nm should raise concern. Third, identity against the parent protein: a supplier calling the product thymosin beta-4 while shipping the heptapeptide is presenting an 889 Da peptide as a 4,963 Da protein, and any mass result exposes that at once. See how to read a COA.

A final practical point about interpreting results from a peptide this small. At 889 Da, TB-500 lies close to the point where mass spectrometry, chromatography and even filtration stop behaving as they do with larger peptides: it slips through molecular weight cut-off membranes that hold back most research peptides, comes off reversed-phase gradients early, and is readily lost in sample-preparation steps intended for proteins. Before trusting results from a workflow borrowed from larger-peptide work, validate recovery — unnoticed losses during processing generate precisely the picture of weak and inconsistent effects this peptide is so often said to produce.

Regulatory position

No jurisdiction has approved TB-500 as a medicine. It is on the World Anti-Doping Agency prohibited list, and in the United States substances related to thymosin beta-4 have been placed in the FDA category of bulk substances ineligible for compounding. Research-grade TB-500 is supplied as a laboratory reference chemical.

Related peptides and comparisons

BPC-157 vs TB-500 is the usual comparison, and the two are also sold together as the Wolverine blend. The intact molecule is covered under full-length thymosin beta-4, and BPC-157 is among the related repair tools.